Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 814INDUSTRY 59OTHER_GOV 14NETWORK 3NIH 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Neoplasms 1Hematologic Diseases 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 388Specimen Handling 376Magnetic Resonance Spectroscopy 328Radiotherapy 306Biopsy 273Cisplatin 258Carboplatin 255Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 183Bevacizumab 181Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 141Taxes 127Docetaxel 122Chemotherapy, Adjuvant 114Oxaliplatin 113fludarabine phosphate 111Methotrexate 108Rituximab 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Blood Specimen Collection × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

NCT00166647 2013-01-11

Thiopurine Methyltransferase Polymorphisms Evaluation

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Withdrawn

Hematologic Diseases, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡